{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T19:53:58Z","timestamp":1788292438242,"version":"build-2803163510"},"reference-count":37,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>People with HIV (PWH) may be at increased risk for severe outcomes with COVID-19 illness compared with people without HIV. Little is known about COVID-19 vaccination coverage and factors associated with primary series completion among PWH.<\/jats:p><\/jats:sec>Objectives<\/jats:title>To evaluate COVID-19 vaccination coverage among PWH and examine sociodemographic, clinical, and community-level factors associated with completion of the primary series and an additional primary dose.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This retrospective cohort study used electronic health record data to assess COVID-19 vaccination information from December 14, 2020, through April 30, 2022, from 8 health care organizations of the Vaccine Safety Datalink project in the US. Participants were adults diagnosed with HIV on or before December 14, 2020, enrolled in a participating site.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>The percentage of PWH with at least 1 dose of COVID-19 vaccine and PWH who completed the COVID-19 vaccine primary series by December 31, 2021, and an additional primary dose by April 30, 2022. Rate ratios (RR) and 95% CIs were estimated using Poisson regression models for factors associated with completing the COVID-19 vaccine primary series and receiving an additional primary dose.<\/jats:p><\/jats:sec>Results<\/jats:title>Among 22\u202f058 adult PWH (mean [SD] age, 52.1 [13.3] years; 88.8% male), 90.5% completed the primary series by December 31, 2021. Among 18\u202f374 eligible PWH who completed the primary series by August 12, 2021, 15\u202f982 (87.0%) received an additional primary dose, and 4318 (23.5%) received a booster dose by April 30, 2022. Receipt of influenza vaccines in the last 2 years was associated with completion of the primary series (RR, 1.17; 95% CI, 1.15-1.20) and an additional primary dose (RR, 1.61; 95% CI, 1.54-1.69). PWH with uncontrolled viremia (HIV viral load \u2265200 copies\/mL) (eg, RR, 0.90 [95% CI, 0.85-0.95] for viral load 200-10\u202f000 copies\/mL vs undetected or &amp;lt;200 copies\/mL for completing the primary series) and Medicaid insurance (eg, RR, 0.89 [95% CI, 0.87-0.90] for completing the primary series) were less likely to be fully vaccinated. By contrast, greater outpatient utilization (eg, RR, 1.07 [95% CI, 1.05-1.09] for \u22657 vs 0 visits for primary series completion) and residence in counties with higher COVID-19 vaccine coverage (eg, RR, 1.06 [95% CI, 1.03-1.08] for fourth vs first quartiles for primary series completion) were associated with primary series and additional dose completion (RRs ranging from 1.01 to 1.21).<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>Findings from this cohort study suggest that, while COVID-19 vaccination coverage was high among PWH, outreach efforts should focus on those who did not complete vaccine series and those who have uncontrolled viremia.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2024.15220","type":"journal-article","created":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T15:33:26Z","timestamp":1717688006000},"page":"e2415220","source":"Crossref","is-referenced-by-count":13,"title":["COVID-19 Vaccination Coverage and Factors Associated With Vaccine Uptake Among People With HIV"],"prefix":"10.1001","volume":"7","author":[{"given":"Rulin C.","family":"Hechter","sequence":"first","affiliation":[{"name":"Kaiser Permanente Southern California, Pasadena, California"},{"name":"Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Qian","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Southern California, Pasadena, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In-Lu Amy","family":"Liu","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Southern California, Pasadena, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina S.","family":"Sy","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Southern California, Pasadena, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denison S.","family":"Ryan","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Southern California, Pasadena, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley","family":"Xu","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Southern California, Pasadena, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua T. B.","family":"Williams","sequence":"additional","affiliation":[{"name":"Denver Health, Denver, Colorado"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola P.","family":"Klein","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Vaccine Study Center, Oakland, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robyn M.","family":"Kaiser","sequence":"additional","affiliation":[{"name":"HealthPartners, Bloomington, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth G.","family":"Liles","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Center for Health Research, Portland, Oregon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason M.","family":"Glanz","sequence":"additional","affiliation":[{"name":"Institute for Health Research, Kaiser Permanente, Denver, Colorado"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa A.","family":"Jackson","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Washington Research Institute, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria E.","family":"Sundaram","sequence":"additional","affiliation":[{"name":"Marshfield Clinic Research Institute, Marshfield, Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric S.","family":"Weintraub","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung Fu","family":"Tseng","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Southern California, Pasadena, California"},{"name":"Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2024,6,6]]},"reference":[{"issue":"1","key":"zoi240510r1","doi-asserted-by":"publisher","first-page":"e24","DOI":"10.1016\/S2352-3018(20)30305-2","article-title":"HIV infection and COVID-19 death: a population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform.","volume":"8","author":"Bhaskaran","year":"2021","journal-title":"Lancet HIV"},{"issue":"7","key":"zoi240510r2","doi-asserted-by":"publisher","first-page":"e2005","DOI":"10.1093\/cid\/ciaa1198","article-title":"Risk factors for coronavirus disease 2019 (COVID-19) death in a population cohort study from the Western Cape Province, South Africa.","volume":"73","author":"Boulle","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"7","key":"zoi240510r3","doi-asserted-by":"publisher","first-page":"e1964","DOI":"10.1093\/cid\/ciaa1339","article-title":"Characteristics, comorbidities, and outcomes in a multicenter registry of patients with human immunodeficiency virus and coronavirus disease 2019.","volume":"73","author":"Dandachi","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"7","key":"zoi240510r4","doi-asserted-by":"publisher","first-page":"e2095","DOI":"10.1093\/cid\/ciaa1605","article-title":"Outcomes of coronavirus disease 2019 (COVID-19) related hospitalization among people with human immunodeficiency virus (HIV) in the ISARIC World Health Organization (WHO) clinical characterization protocol (UK): a prospective observational study.","volume":"73","author":"Geretti","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"5","key":"zoi240510r5","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1111\/hiv.v22.5","article-title":"Immune deficiency is a risk factor for severe COVID-19 in people living with HIV.","volume":"22","author":"Hoffmann","year":"2021","journal-title":"HIV Med"},{"issue":"2","key":"zoi240510r6","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.37069","article-title":"COVID-19 outcomes among persons living with or without diagnosed HIV infection in New York State.","volume":"4","author":"Tesoriero","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"8","key":"zoi240510r8","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.7326\/M20-8283","article-title":"COVID-19 inequities across multiple racial and ethnic groups: results from an integrated health care organization.","volume":"174","author":"Nau","year":"2021","journal-title":"Ann Intern Med"},{"issue":"49","key":"zoi240510r10","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.15585\/mmwr.mm6949e1","article-title":"The Advisory Committee on Immunization Practices\u2019 interim recommendation for allocating initial supplies of COVID-19 vaccine\u2014United States, 2020.","volume":"69","author":"Dooling","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"9","key":"zoi240510r11","doi-asserted-by":"publisher","first-page":"329","DOI":"10.15585\/mmwr.mm7009e4","article-title":"The Advisory Committee on Immunization Practices\u2019 interim recommendation for use of Janssen COVID-19 vaccine\u2014United States, February 2021.","volume":"70","author":"Oliver","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"zoi240510r12","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab438","article-title":"The effectiveness of the two-dose BNT162b2 vaccine: analysis of real-world data.","author":"Chodick","year":"2022","journal-title":"Clin Infect Dis"},{"key":"zoi240510r13","author":"Brosh-Nissimov","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"zoi240510r14","doi-asserted-by":"publisher","DOI":"10.1101\/2021.07.08.21259776","article-title":"Effectiveness of SARS-CoV-2 mRNA vaccines for preventing Covid-19 hospitalizations in the United States.","author":"Tenforde","journal-title":"medRxiv"},{"issue":"42","key":"zoi240510r17","doi-asserted-by":"publisher","first-page":"5390","DOI":"10.1016\/j.vaccine.2014.07.073","article-title":"The Vaccine Safety Datalink: successes and challenges monitoring vaccine safety.","volume":"32","author":"McNeil","year":"2014","journal-title":"Vaccine"},{"issue":"6","key":"zoi240510r19","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/j.vaccine.2017.01.007","article-title":"Human papillomavirus vaccine series completion in boys before and after recommendation for routine immunization.","volume":"35","author":"Ackerson","year":"2017","journal-title":"Vaccine"},{"issue":"12","key":"zoi240510r20","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.2105\/AJPH.2015.302840","article-title":"Quadrivalent human papillomavirus vaccine initiation in boys before and since routine use: Southern California, 2009-2013.","volume":"105","author":"Hechter","year":"2015","journal-title":"Am J Public Health"},{"issue":"6","key":"zoi240510r21","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/j.vaccine.2020.12.076","article-title":"Completion of the two-dose recombinant zoster vaccine series in adults 50 years and older.","volume":"39","author":"Ackerson","year":"2021","journal-title":"Vaccine"},{"issue":"49","key":"zoi240510r22","doi-asserted-by":"publisher","first-page":"7460","DOI":"10.1016\/j.vaccine.2023.11.012","article-title":"Factors associated with uptake of bivalent mRNA COVID-19 vaccines in a large US health care system.","volume":"41","author":"Bruxvoort","year":"2023","journal-title":"Vaccine"},{"issue":"1","key":"zoi240510r24","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s12874-018-0519-5","article-title":"Comparing performance between log-binomial and robust Poisson regression models for estimating risk ratios under model misspecification.","volume":"18","author":"Chen","year":"2018","journal-title":"BMC Med Res Methodol"},{"issue":"24","key":"zoi240510r26","doi-asserted-by":"publisher","first-page":"3636","DOI":"10.1016\/j.vaccine.2023.04.075","article-title":"Vaccine effectiveness of the mRNA-1273 3-dose primary series against COVID-19 in an immunocompromised population: a prospective observational cohort study.","volume":"41","author":"Ku","year":"2023","journal-title":"Vaccine"},{"issue":"1","key":"zoi240510r28","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s12877-021-02673-1","article-title":"Age is the main determinant of COVID-19 related in-hospital mortality with minimal impact of pre-existing comorbidities, a retrospective cohort study.","volume":"22","author":"Henkens","year":"2022","journal-title":"BMC Geriatr"},{"issue":"1","key":"zoi240510r29","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s43856-021-00006-2","article-title":"Analysis of sex-specific risk factors and clinical outcomes in COVID-19.","volume":"1","author":"Jun","year":"2021","journal-title":"Commun Med (Lond)"},{"issue":"1","key":"zoi240510r30","doi-asserted-by":"publisher","first-page":"6317","DOI":"10.1038\/s41467-020-19741-6","article-title":"Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission.","volume":"11","author":"Peckham","year":"2020","journal-title":"Nat Commun"},{"issue":"10229","key":"zoi240510r31","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.","volume":"395","author":"Zhou","year":"2020","journal-title":"Lancet"},{"issue":"8","key":"zoi240510r32","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad400","article-title":"Risk Factors for SARS-CoV-2 infection and severe outcomes among people with human immunodeficiency virus: cohort study.","volume":"10","author":"Hanna","year":"2023","journal-title":"Open Forum Infect Dis"},{"issue":"3","key":"zoi240510r33","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1093\/ije\/dyac007","article-title":"Fighting a pandemic: sociodemographic disparities and coronavirus disease-2019 vaccination gaps-a population study.","volume":"51","author":"Benderly","year":"2022","journal-title":"Int J Epidemiol"},{"issue":"4","key":"zoi240510r34","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.amepre.2021.10.008","article-title":"Racial and ethnic disparities in COVID-19 vaccination coverage: the contribution of socioeconomic and demographic factors.","volume":"62","author":"Williams","year":"2022","journal-title":"Am J Prev Med"},{"issue":"1","key":"zoi240510r35","doi-asserted-by":"publisher","first-page":"18443","DOI":"10.1038\/s41598-021-97705-6","article-title":"Social and economic inequality in coronavirus disease 2019 vaccination coverage across Illinois counties.","volume":"11","author":"Liao","year":"2021","journal-title":"Sci Rep"},{"issue":"12","key":"zoi240510r36","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1377\/hlthaff.2021.01055","article-title":"Sociodemographic disparities in access to COVID-19 vaccines upon initial rollout in Florida.","volume":"40","author":"Attonito","year":"2021","journal-title":"Health Aff (Millwood)"},{"issue":"5","key":"zoi240510r37","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/j.vaccine.2021.12.048","article-title":"Monitoring vaccine safety using the Vaccine Safety Datalink: assessing capacity to integrate data from immunization information systems.","volume":"40","author":"Groom","year":"2022","journal-title":"Vaccine"},{"key":"zoi240510r7","unstructured":"Centers for Disease Control and Prevention (CDC). Underlying medical conditions associated with higher risk for severe COVID-19: information for healthcare professionals. Updated April 12, 2024. Accessed October 14, 2021. https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/hcp\/clinical-care\/underlyingconditions.html"},{"key":"zoi240510r9","unstructured":"Centers for Disease Control and Prevention (CDC). Guidance for COVID-19 and people with HIV. Updated February 22, 2022. Accessed November 10, 2021. https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/covid-19-and-persons-hiv-interim-guidance\/interim-guidance-covid-19-and-persons-hiv"},{"key":"zoi240510r15","unstructured":"Centers for Disease Control and Prevention (CDC). COVID-19 vaccines for moderately to severely immunocompromised people. Updated March 8, 2024. Accessed November 10, 2021. https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/vaccines\/recommendations\/immuno.html"},{"key":"zoi240510r16","unstructured":"Centers for Disease Control and Prevention (CDC). Archived COVID-19 vaccination schedules. Accessed May 16, 2023. https:\/\/www.cdc.gov\/vaccines\/covid-19\/clinical-considerations\/archived-covid-19-vacc-schedule.html"},{"key":"zoi240510r18","unstructured":"Centers for Disease Control and Prevention (CDC). Use of COVID-19 vaccines in the United States: interim clinical considerations. October 14, 2021. Accessed October 14, 2021. https:\/\/www.cdc.gov\/vaccines\/covid-19\/clinical-considerations\/covid-19-vaccines-us.html"},{"key":"zoi240510r23","unstructured":"Centers for Disease Control and Prevention (CDC). COVID data tracker: nationwide COVID-19 infection-induced antibody seroprevalence (commercial laboratories). Updated May 19, 2024. Accessed December 7, 2021. https:\/\/covid.cdc.gov\/covid-data-tracker\/#national-lab"},{"key":"zoi240510r25","unstructured":"Centers for Disease Control and Prevention (CDC). COVID data tracker: COVID-19 Update for the United States. Accessed October 13, 2021. https:\/\/covid.cdc.gov\/covid-data-tracker\/#vaccinations_vacc-total-admin-rate-total"},{"key":"zoi240510r27","unstructured":"Centers for Disease Control and Prevention. Risk for COVID-19 infection, hospitalization, and death by age group. Accessed May 5, 2023. https:\/\/archive.cdc.gov\/#\/details?url=https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/covid-data\/investigations-discovery\/hospitalization-death-by-age.html"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2819636\/hechter_2024_oi_240510_1717008667.37287.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T15:33:33Z","timestamp":1717688013000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2819636"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,6]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6,3]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.15220","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,6]]}}}